nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Author index
|
|
|
2014 |
50 |
S1 |
p. S17- 1 p. |
artikel |
2 |
Editorial Board
|
|
|
2014 |
50 |
S1 |
p. ii- 1 p. |
artikel |
3 |
K Effective combinations of targeted therapies for colon cancer based on insights in cross-talk between signaling pathways
|
Bernards, R. |
|
2014 |
50 |
S1 |
p. S2-S3 2 p. |
artikel |
4 |
Neoadjuvant radiotherapy (5 × 5 Gy) – immediate vs delayed surgery
|
Bujko, K. |
|
2014 |
50 |
S1 |
p. S4- 1 p. |
artikel |
5 |
P7 A single institution's experience in rectal cancer
|
Acharya, B. |
|
2014 |
50 |
S1 |
p. S11- 1 p. |
artikel |
6 |
P16 Cancer of the anus: a 5 year review of cases at Gondar University Hospital
|
Beza, A.D. |
|
2014 |
50 |
S1 |
p. S14- 1 p. |
artikel |
7 |
P2 Cardamonin suppresses the proliferation of gastric cancer cells by promoting β-catenin degradation
|
Naidu, V.G.M. |
|
2014 |
50 |
S1 |
p. S9- 1 p. |
artikel |
8 |
P12 Colorectal cancer in Morocco: a retrospective study
|
Ayoujil, A. |
|
2014 |
50 |
S1 |
p. S13- 1 p. |
artikel |
9 |
P9 Comparison of cetuximab and bevacizumab as first-line treatment in KRAS wild type advanced colorectal cancer patients: a retrospective analysis
|
Zhang, Q. |
|
2014 |
50 |
S1 |
p. S12- 1 p. |
artikel |
10 |
P6 Comparison of outcomes following minimally invasive versus transhiatal esophagectomy for esophageal cancer; a case control study
|
Rizvi, F. |
|
2014 |
50 |
S1 |
p. S10-S11 2 p. |
artikel |
11 |
PG 4.1 Aims of combined modality therapy in non-metastatic rectal cancer
|
Gerard, J.P. |
|
2014 |
50 |
S1 |
p. S4- 1 p. |
artikel |
12 |
PG 1.2 Anatomy of rectum: surgeon's perspective
|
Weitz, J. |
|
2014 |
50 |
S1 |
p. S1- 1 p. |
artikel |
13 |
P4 Gastric cancer and CNS involvement registry
|
Feilchenfeldt, J. |
|
2014 |
50 |
S1 |
p. S10- 1 p. |
artikel |
14 |
PG 4.2 Can neoadjuvant chemotherapy replace radiochemotherapy?
|
Arnold, D. |
|
2014 |
50 |
S1 |
p. S4- 1 p. |
artikel |
15 |
PG 5.1 Do T3 rectal cancers always need radiochemotherapy?
|
Glynne-Jones, R. |
|
2014 |
50 |
S1 |
p. S5- 1 p. |
artikel |
16 |
PG 8.4 Do we really need perioperative chemotherapy for resectable liver metastases?
|
Weitz, J. |
|
2014 |
50 |
S1 |
p. S8- 1 p. |
artikel |
17 |
PG 4.4 Early and late toxicity of radiotherapy for rectal cancer – is there a difference between chemoradiation and 5×5 Gy?
|
Haustermans, K. |
|
2014 |
50 |
S1 |
p. S4-S5 2 p. |
artikel |
18 |
PG 2.2 Endoscopic resection: When is EMR/ESD sufficient?
|
Messmann, H. |
|
2014 |
50 |
S1 |
p. S2- 1 p. |
artikel |
19 |
PG 1.1 Epidemiology of colorectal cancer: Risk factors, genetic predisposition
|
Folprecht, G. |
|
2014 |
50 |
S1 |
p. S1- 1 p. |
artikel |
20 |
PG 5.3 How to manage stenosing rectal cancer: Stoma and preoperative radiochemotherapy OR primary surgery
|
D'Hoore, A. |
|
2014 |
50 |
S1 |
p. S5- 1 p. |
artikel |
21 |
PG 6.1 Immediate surgery or clinical follow-up after complete response?
|
Habr-Gama, A. |
|
2014 |
50 |
S1 |
p. S5-S6 2 p. |
artikel |
22 |
PG 6.3 Is there a need for adjuvant chemotherapy after combined modality treatment?
|
Van Cutsem, E. |
|
2014 |
50 |
S1 |
p. S6- 1 p. |
artikel |
23 |
PG 7.3 Leave it all in? When to (not) resect the primary?
|
Lordick, F. |
|
2014 |
50 |
S1 |
p. S7- 1 p. |
artikel |
24 |
PG 7.2 Limits of resectability and how to overcome them
|
Evrard, S. |
|
2014 |
50 |
S1 |
p. S6-S7 2 p. |
artikel |
25 |
PG 7.1 Liver First Approach in synchronous liver metastases from colorectal cancer
|
Mentha, G. |
|
2014 |
50 |
S1 |
p. S6- 1 p. |
artikel |
26 |
PG 1.4 Molecular differences between colon and rectal cancer
|
Pilati, C. |
|
2014 |
50 |
S1 |
p. S1- 1 p. |
artikel |
27 |
PG 2.1 MRI, CT and endosonography: Do we need them all?
|
Brown, G. |
|
2014 |
50 |
S1 |
p. S2- 1 p. |
artikel |
28 |
PG 2.4 Predicting lymph node metastase in T1 rectal cancer
|
Nagtegaal, I.D. |
|
2014 |
50 |
S1 |
p. S2- 1 p. |
artikel |
29 |
PG 6.2 Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: disease free survival results at interim analysis
|
Schmoll, H-J. |
|
2014 |
50 |
S1 |
p. S6- 1 p. |
artikel |
30 |
PG 5.2 Quality of life after surgery for rectal cancer
|
Pucciarelli, S. |
|
2014 |
50 |
S1 |
p. S5- 1 p. |
artikel |
31 |
PG 8.3 Recurrence patterns after resection of liver metastases
|
Sorbye, H. |
|
2014 |
50 |
S1 |
p. S8- 1 p. |
artikel |
32 |
PG 8.2 Surgery versus radiofrequency ablation (Lessons from the CLOCC trial)
|
Ruers, T.J.M. |
|
2014 |
50 |
S1 |
p. S7- 1 p. |
artikel |
33 |
PG 8.1 Surgical strategies to synchronous rectal liver metastases: Chemotherapy before or after surgery or both
|
Nordlinger, B. |
|
2014 |
50 |
S1 |
p. S7- 1 p. |
artikel |
34 |
PG 3.4 The treatment of T4 rectal cancer, do we always need an exenterative procedure?
|
Rutten, H.J.T. |
|
2014 |
50 |
S1 |
p. S3-S4 2 p. |
artikel |
35 |
PG 3.2 Total mesorectal excision: open, laparoscopic or robotic
|
Pigazzi, A. |
|
2014 |
50 |
S1 |
p. S3- 1 p. |
artikel |
36 |
PG 2.3 Transanal endoscopic microsurgery
|
Cunningham, C. |
|
2014 |
50 |
S1 |
p. S2- 1 p. |
artikel |
37 |
PG 3.3 Ultra-low resection vs wide perineal resection
|
Holm, T. |
|
2014 |
50 |
S1 |
p. S3- 1 p. |
artikel |
38 |
PG 1.3 Understanding rectal cancer: biological basis, anatomy of rectum: comment from the radiation oncologist
|
Haustermans, K. |
|
2014 |
50 |
S1 |
p. S1- 1 p. |
artikel |
39 |
PG 3.1 What is “good quality” in rectal cancer surgery? The pathologist's perspective
|
Nagtegaal, I.D. |
|
2014 |
50 |
S1 |
p. S3- 1 p. |
artikel |
40 |
P10 Induction chemotherapy followed by chemoradiotherapy before surgery for rectal adenocarcinoma
|
Akbar, A. |
|
2014 |
50 |
S1 |
p. S12- 1 p. |
artikel |
41 |
P13 Novel strategies for advanced pancreas cancer
|
Osada, S. |
|
2014 |
50 |
S1 |
p. S13- 1 p. |
artikel |
42 |
P17 Outcome of salvage surgery for recurrent anal squamous cell carcinoma
|
Assalino, M. |
|
2014 |
50 |
S1 |
p. S14- 1 p. |
artikel |
43 |
P19 Pancreatic cancer in Morocco: the epidemiological evidence
|
Hami, H. |
|
2014 |
50 |
S1 |
p. S15- 1 p. |
artikel |
44 |
P1 Piperlongumine inhibits growth potential of gastric cancer cells by targeting PI3K/Akt/mTOR signaling pathway
|
Shrivastava, S. |
|
2014 |
50 |
S1 |
p. S9- 1 p. |
artikel |
45 |
P8 Preoperative radiotherapy or radiochemotherapy for locally advanced rectal cancer patients: single centre experience
|
Vasiliou, V. |
|
2014 |
50 |
S1 |
p. S11- 1 p. |
artikel |
46 |
P15 Prevalence and clinicopathological correlation of carcinoid in appendectomy specimens in Sharjah, United Arab Emirates (UAE)
|
Anwar, K. |
|
2014 |
50 |
S1 |
p. S14- 1 p. |
artikel |
47 |
P14 Retrospective series of 22 cases with small bowel adenocarcinoma and review of the literature
|
Sagmeister, M. |
|
2014 |
50 |
S1 |
p. S13- 1 p. |
artikel |
48 |
P11 Risk factors of lymph node metastasis in rectal cancer following preoperative chemoradiotherapy
|
Park, J.W. |
|
2014 |
50 |
S1 |
p. S12-S13 2 p. |
artikel |
49 |
P5 Stomach cancer in Niamey: first results from the Niger Cancer Registry
|
Mamoudou Garba, S. |
|
2014 |
50 |
S1 |
p. S10- 1 p. |
artikel |
50 |
P3 Surgical management of gastric cancer: single centre experience from a developing country
|
Khan, M.K. |
|
2014 |
50 |
S1 |
p. S9-S10 2 p. |
artikel |
51 |
P18 Therapeutic effect of immune reaction due to cryoablation
|
Osada, S. |
|
2014 |
50 |
S1 |
p. S14- 1 p. |
artikel |